US EditionPublished • loading... • Updated
Solventum Completes Acquisition of Acera Surgical
Solventum's $725 million acquisition of Acera Surgical aims to enhance regenerative wound care with expected $90 million sales in 2025 and EPS accretion by 2027.
- On Dec. 23, 2025, Solventum completed the acquisition of Acera Surgical in PAUL, Minn., a bioscience company focused on regenerative wound care materials.
- Adding Acera's technology strengthens Solventum's wound care line by incorporating synthetic tissue matrix technology, with Acera expected to generate approximately $90 million in sales in 2025.
- Solventum agreed to pay $725 million upfront and up to $125 million contingent payments, with LLC and McDermott Will & Schulte LLP advising; the deal is immaterial to Q4 2025 results.
- The company projects near-term dilution followed by accretion as the transaction is expected to be slightly dilutive to adjusted EPS in 2026 and accretive beginning in 2027, Bryan Hanson, chief executive officer of Solventum, said.
- Solventum warned of broad forward-looking risks including regulatory and legal exposure, citing antitrust, FCPA, product liability, supply-chain, PFAS liabilities, and Spin-Off-related separation agreements with 3M Company.
Insights by Ground AI
30 Articles
30 Articles
The Norfolk Daily News+28 Reposted by 28 other sources
Solventum Completes Acquisition of Acera Surgical
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency
Coverage Details
Total News Sources30
Leaning Left0Leaning Right0Center12Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
